Bank of Montreal Can Sells 12,417 Shares of Haleon plc (NYSE:HLN)

Bank of Montreal Can lowered its position in Haleon plc (NYSE:HLN) by 1.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 704,757 shares of the company’s stock after selling 12,417 shares during the quarter. Bank of Montreal Can’s holdings in Haleon were worth $6,723,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Sierra Ocean LLC purchased a new stake in shares of Haleon in the 4th quarter worth $26,000. Versant Capital Management Inc grew its holdings in Haleon by 2,029.1% during the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after acquiring an additional 3,348 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in Haleon during the 4th quarter valued at about $35,000. Toronto Dominion Bank raised its holdings in shares of Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock valued at $38,000 after purchasing an additional 3,470 shares in the last quarter. Finally, Spire Wealth Management purchased a new stake in shares of Haleon in the 4th quarter worth approximately $39,000. Institutional investors own 6.67% of the company’s stock.

Haleon Stock Performance

Shares of HLN opened at $10.05 on Monday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock has a 50-day moving average of $10.04 and a two-hundred day moving average of $9.81. The stock has a market cap of $45.38 billion, a P/E ratio of 29.54, a P/E/G ratio of 2.82 and a beta of 0.24. Haleon plc has a one year low of $8.03 and a one year high of $10.80.

Haleon (NYSE:HLN) last issued its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. As a group, research analysts predict that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The business also recently declared a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be given a dividend of $0.1166 per share. This is an increase from Haleon’s previous — dividend of $0.05. This represents a yield of 1.6%. The ex-dividend date is Friday, April 25th. Haleon’s dividend payout ratio (DPR) is currently 58.97%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on HLN shares. Morgan Stanley downgraded shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. HSBC reaffirmed a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Finally, Hsbc Global Res cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Six equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Haleon presently has a consensus rating of “Hold” and an average price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.